WO2022166062A1 - Mécanisme d'ancrage de valvule cardiaque et dispositif de prothèse de valvule cardiaque - Google Patents

Mécanisme d'ancrage de valvule cardiaque et dispositif de prothèse de valvule cardiaque Download PDF

Info

Publication number
WO2022166062A1
WO2022166062A1 PCT/CN2021/099451 CN2021099451W WO2022166062A1 WO 2022166062 A1 WO2022166062 A1 WO 2022166062A1 CN 2021099451 W CN2021099451 W CN 2021099451W WO 2022166062 A1 WO2022166062 A1 WO 2022166062A1
Authority
WO
WIPO (PCT)
Prior art keywords
anchoring
heart valve
spacer
anchoring mechanism
tissue
Prior art date
Application number
PCT/CN2021/099451
Other languages
English (en)
Chinese (zh)
Inventor
赵婧
刘祥
闻靖
Original Assignee
上海臻亿医疗科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海臻亿医疗科技有限公司 filed Critical 上海臻亿医疗科技有限公司
Publication of WO2022166062A1 publication Critical patent/WO2022166062A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body

Definitions

  • the utility model belongs to the technical field of medical devices, in particular to a heart valve anchoring mechanism and a heart valve prosthesis device.
  • Transcatheter mitral valve replacement is a method of catheter intervention.
  • the artificial valve is compressed into the delivery system outside the body, along the vascular path or through the apex, to the human mitral valve annulus, and the artificial valve is released. It is fixed at the mitral valve annulus to replace the native valve.
  • TMVR does not require extracorporeal circulation auxiliary devices, has less trauma, quicker recovery of patients, and significantly improved postoperative hemodynamic indicators.
  • valve anchoring Some of the existing mitral valve designs use clipping leaflets or grasping the valve leaflets for anchoring, both of which will pull the chordae tendineae and cause damage to the native valve leaflets. There is also anchoring through the Oversize design of the stent body. With this anchoring method, the stent compresses the tissue, which affects the contraction of the heart, and there is a risk of conduction block. There are also attempts to anchor by connecting a plate-shaped spacer to the end of the pull rope, but the spacer alone cannot form an effective anchorage.
  • the utility model provides a heart valve anchoring mechanism and a heart valve prosthesis device, which can solve the above-mentioned defects in the prior art.
  • a heart valve anchoring mechanism for anchoring a heart valve the end of the heart valve is provided with an axially extending connector, the anchoring mechanism is configured to be fixed to the end of the connector, the anchoring mechanism It includes a spacer including a first surface attached to the tissue and a second surface opposite the first surface and an anchor, the anchor including a plurality of anchoring units secured to the the second surface.
  • the plurality of anchoring units of the anchor are respectively attached and anchored to the tissue, and are also attached to the tissue surface through one surface of the spacer.
  • the spacer can provide a relatively large surface area, which can prevent stress concentration and prevent the anchor from affecting the tissue.
  • a force will be generated on the spacer, and the force can make the spacer and the tissue adhere closely, thus playing the role of sealing the wound, which is beneficial to the anchoring of the anchoring mechanism. ; Through the cooperation of the spacer and the anchoring unit, a better anchoring effect can be provided.
  • the spacer is configured to conform to the morphology of the apical epicardium. Such a structure enables the spacer to always closely adhere to the apical epicardium during the cardiac cycle, which is beneficial to the anchoring of the anchoring mechanism and the tissue, and at the same time, it also has a good occlusion effect.
  • the first surface of the spacer is configured to protrude in a direction away from the heart valve, and the spacer is attached to the apical epicardium through the protruding first surface away from the apex, so that the spacer can be more adapted to the outside of the heart. Morphology of the membrane to reduce stress damage to the apical portion.
  • the spacer is configured as a frame structure, and the surface of the spacer is further provided with a coating layer.
  • the frame structure can make the spacer have a certain flexibility to adapt to the dynamic cardiac circulation, and the membrane layer has a certain sealing effect to prevent blood penetration.
  • the spacer is configured as a sheet-like structure, which has the advantage of being simple to form.
  • the anchoring unit is configured to bulge in a direction away from the heart valve.
  • the anchor can be adapted to the external shape of the entire ventricle, the anchoring unit can better grasp the tissue, and the anchoring is firm.
  • the anchoring unit is configured such that one end is connected to the second surface, the other end first extends to a side away from the heart valve, and then bends to extend toward the heart valve side, and the end fit with the organization.
  • the anchoring unit is made of shape memory material. Therefore, the anchoring unit can be crimped into the delivery device for delivery, and can return to its original state for anchoring after being released to the target location.
  • the center of the spacer is configured with a central hole for fixing the connector.
  • a plurality of the anchoring units are evenly distributed along the center circumference of the second surface of the second spacer to provide stable anchoring force, and the anchoring units are fixed between the central hole and the spacer Between the edges of the anchoring unit, the end of the anchoring unit is attached to the tissue through a spacer to prevent damage to the tissue by the end of the anchoring unit.
  • the utility model also provides a heart valve prosthesis device using any of the heart valve anchoring mechanisms described above.
  • the multiple anchoring units of the anchor are respectively attached and anchored to the tissue, and are also attached to the tissue surface through one surface of the spacer, and the spacer can provide relative Large surface area to prevent stress concentration and wear of the anchor to the tissue; in addition, when the anchor unit is attached to the tissue, a force will be generated on the spacer, which can make the spacer adhere tightly to the tissue, thereby It plays the role of sealing the wound and enhancing the anchoring effect; through the cooperation of the spacer and the anchoring unit, it can provide a better anchoring effect.
  • the spacer is attached to the apical epicardium through the first surface protruding away from the centrifugal apex, and the spacer is configured in a manner that conforms to the shape of the apical epicardium during the cardiac cycle , so that the spacer can be more adapted to the shape of the apical epicardium, so as to reduce the stress damage to the apical part, and the spacer can be closely attached to the apical epicardium, which is beneficial to enhance the anchoring effect of the anchoring mechanism and the tissue.
  • the anchoring unit is configured to protrude toward the direction away from the heart valve, and such a structure can make the anchor fit the external shape of the entire ventricle, The anchoring unit can better grasp the tissue, and the anchoring is firm.
  • the heart valve prosthesis device of the present invention can be delivered by the atrial septal route. Compared with the apical route, the atrial septal route through the femoral vein is less traumatic and has a wider audience.
  • FIG. 1 is a schematic diagram of the overall structure of the heart valve prosthesis device according to Embodiment 1 of the present invention.
  • FIG. 2A is a schematic diagram of the overall structure of the anchoring mechanism of Embodiment 1 of the present invention.
  • FIG. 2B is a cross-sectional structural schematic diagram of the anchoring mechanism of Embodiment 1 of the present invention.
  • FIG. 2C is a schematic diagram of the overall structure of a spacer according to Embodiment 1 of the present invention.
  • FIG. 3A is a schematic diagram of the overall structure of another anchoring mechanism according to Embodiment 1 of the present invention.
  • FIG. 3B is a cross-sectional structural schematic diagram of the anchoring mechanism of Embodiment 1 of the present invention.
  • FIG. 4A is a schematic structural diagram of the initial stage of implantation of the heart valve prosthesis device according to Embodiment 1 of the present invention.
  • FIG. 4B is a schematic structural diagram of the release stage of the heart valve prosthesis device according to Embodiment 1 of the present invention.
  • FIG. 4C is a schematic structural diagram of the heart valve prosthesis device released according to Embodiment 1 of the present invention.
  • valve prosthesis 100 first region 101; second region 102; third region 103; stent 110; ventricular anchor 200; Q; first surface 2211; second surface 2212.
  • the terms “installed”, “connected” and “connected” should be understood in a broad sense, for example, it may be a fixed connection or a connectable connection.
  • Detachable connection, or integral connection may be mechanical connection or electrical connection; may be direct connection, or indirect connection through an intermediate medium, or internal communication between two components.
  • the specific meanings of the above terms in the present invention can be understood in specific situations.
  • FIGS. 1-4C are schematic structural diagrams of this embodiment, wherein the heart valve prosthesis device is composed of a valve prosthesis 100 (also referred to as a heart valve) and a
  • the ventricular anchoring part 200 is composed of the valve prosthesis 100 including the stent 110, the skirt and the artificial valve leaflets.
  • the heart valve prosthesis device of this embodiment can be longitudinally divided into a first region 101 , a second region 102 and a third region 103 .
  • the first region 101 is attached to the original mitral valve.
  • the second area 102 is used to carry the artificial valve leaflets, and at the same time relies on the support on the tissue to play a certain role in fixing and sealing;
  • the third area 103 is The anchoring mechanism of the heart valve in the left ventricle prevents the prosthesis from being impacted by blood to the left atrium when the prosthesis is closed.
  • stent 110 can provide several functions for valve prosthesis 100, including serving as the main structure of the valve, carrying internal prosthetic leaflets, serving as a seal to inhibit paravalvular leakage between valve prosthesis 100 and the native valve, and delivering The connection structure of the system (hanging ears or fixed ears), etc.
  • the stent 110 is woven or cut.
  • the stent 110 is made of nickel-titanium alloy or other biocompatible materials with shape memory properties, and elastically or plastically deformable materials, such as balloons, can also be selected. Expandable material.
  • the bracket 110 is a columnar structure with open ends, such as a cylinder, an ellipse column, etc., and its cross-section is configured as a circle, an ellipse, a petal shape, a round shape, a D shape, and the like.
  • the stent 110 is constructed as a grid-like structure, which is composed of a number of closed geometric cells arranged, such as diamond, square, heart, teardrop, etc., so that the stent 110 can be compressed into the sheath when loaded, and can be recovered when released. undisturbed.
  • the prosthetic leaflets are dynamically switched between open and closed states, in which the prosthetic leaflets are closed or joined in sealing abutment.
  • the prosthetic valve leaflets can be formed from any suitable material or combination of materials, and in some embodiments, biological tissue such as chemically stable tissue from a heart valve from an animal such as a pig, or pericardial tissue from an animal such as bovine (bovine pericardium) or sheep (sheep pericardium) or pig (porcine pericardium) or equine (horse pericardium), preferably bovine pericardium tissue.
  • Prosthetic leaflets can also be made from small intestinal submucosal tissue, in addition, synthetic materials can also be used for the prosthetic leaflets, such as expanded polytetrafluoroethylene or polyester; Ether urethanes, segmented polyether urethanes, silicone polyether urethanes, silicone-polycarbonate urethanes, and ultra-high molecular weight polyethylene.
  • synthetic materials such as expanded polytetrafluoroethylene or polyester; Ether urethanes, segmented polyether urethanes, silicone polyether urethanes, silicone-polycarbonate urethanes, and ultra-high molecular weight polyethylene.
  • biocompatible polymers can be used for prosthetic valve leaflets, optionally including polyolefins, elastomers, polyethylene glycol, polyethersulfone, polysulfone, polyvinylpyrrolidone, polyvinyl chloride , other fluoropolymers, silicone polyesters, siloxane polymers and/or oligomers, and/or polylactones, and block copolymers using them.
  • the prosthetic leaflets have a surface that is treated (or reacted with) an anticoagulant, including, but not limited to, heparinized polymers.
  • the skirt can be a single-layer structure, or a double-layer structure inside and outside. Knitted, woven, woven polyester fabrics, PTFE, ePTFE and other materials can be selected, which mainly play the role of sealing and prevent backflow.
  • the ventricular anchoring portion 200 includes an anchoring mechanism 220 and a connector 210.
  • the connector 210 extends in the axial direction of the heart valve and is disposed at the end of the stent 110, and the anchoring mechanism 220 is fixed to the connector. the end of the piece 210.
  • the extension structure extending from the end points of several rhombus geometric units at one end of the stent 110 is connected with the end of the connecting piece 210 , such as suture connection.
  • the connecting member 210 provides traction for the stent 110 to prevent the stent 110 from being displaced to the left ventricle due to the impact of blood when the heart contracts.
  • the connector 210 may be, for example, a pull cord, wire, or rod-like structure, etc., and may be made of, for example, a biocompatible polymeric material including, but not limited to, ultra-high molecular weight polyethylene (UHMWPE), polytetrafluoroethylene, and the like.
  • UHMWPE ultra-high molecular weight polyethylene
  • the connector 210 may be inelastic to provide a more robust stent anchoring force, or elastic to provide a higher degree of stretch compliance during the cardiac cycle.
  • the connector 210 may be made of a bioabsorbable material and thereby provide temporary fixation until endothelialization between the prosthesis and assembly is sufficient to provide an anchoring force for the valve prosthesis.
  • the connecting member includes a pulling rope, a connecting wire or a connecting rod, and the like.
  • the anchoring mechanism 220 includes a spacer 221 and an anchor, and the spacer 221 includes a first surface 2211 and a second surface 2212 opposite to the first surface 2211 ,
  • the anchor includes a plurality of anchor units 222 secured to the second surface 2212 .
  • the plurality of anchoring units 222 of the anchor are respectively attached and anchored to the tissue, and are also attached to the tissue surface through one surface of the spacer 221.
  • the spacer 221 can provide a relatively large surface area, which can prevent stress concentration, Prevent the wear of the multiple anchoring units to the tissue; in addition, when the anchoring unit 222 is attached to the tissue, it will generate a force on the spacer 221, and the force can make the spacer 221 closely adhere to the tissue, so as to block
  • the role of the wound is also beneficial to enhance the anchoring stability of the anchoring mechanism 220 . In this embodiment, better anchoring effect can be provided through the cooperation between the spacer 221 and the anchoring unit 222 .
  • the first surface 2211 of the spacer 221 is configured to bulge away from the heart valve.
  • the anchoring unit 222 is fixed on the second surface 2212 of the spacer 221 , the first surface 2211 of the spacer 221 is curved around the apical epicardium and roughly conforms to the outer surface of the apex, and the end of the anchoring unit 222 is in contact with the tissue through the spacer 221 , to reduce stress damage to the apex of the heart from the ends of the plurality of anchoring units 222 .
  • the spacer 221 is configured in a manner that conforms to the morphology of the apical epicardium during the cardiac cycle.
  • the spacer 221 is sufficiently flexible, for example, the spacer 221 is configured as a semi-rigid semi-elastic structure, or a flexible structure, which can conform to the apical portion of the heart during a dynamic cardiac cycle, so that it always closely fits the apex during the cardiac cycle
  • the outer membrane provides excellent occlusion effect, and at the same time makes the anchoring mechanism 220 firmly anchored.
  • the spacer 221 is configured as a frame structure, and the surface of the spacer 221 is further provided with a coating layer.
  • the frame structure enables the spacer 221 to have good flexibility to accommodate dynamic cardiac circulation, and the frame structure can be more easily crimped into the delivery device for delivery.
  • the frame structure can be cut, manufactured or woven, and the frame structure can be prepared from nickel-titanium alloy, stainless steel, carbon fiber and other materials.
  • the coating layer can be made of impermeable materials, such as polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene (ePTFE), polypropylene, polyester, animal pericardial tissue, etc. The coating layer can prevent blood penetration.
  • the spacer 221 is configured as a sheet-like structure, as shown in FIG. 2A and FIG. 2B , the sheet-like structure has the advantage of being simple to form, and at the same time, the sheet-like structure can provide better sealing, keep it with the tissue close adhesion between.
  • the spacer 221 of this embodiment can be selected from soft and biocompatible materials such as PE, PTFE, silica gel, etc., thereby reducing the probability of rejection reaction, reducing the wear and tear of cardiac tissue, and thereby improving the safety of patients.
  • the anchor includes three or more anchoring units 222.
  • the anchoring units 222 are configured to protrude in a direction away from the heart valve. That is, the anchoring unit 222 is configured as an anchor claw structure, one end of the anchoring unit 222 extends toward the second surface 2212 of the spacer 221 , and the other end extends toward the direction of the heart valve.
  • the anchoring unit forms the anchor hook structure of the ship anchor.
  • a smooth arc transition is adopted between the extension structures of the anchoring unit 222 in two directions, and an arc-shaped curved surface is formed between the anchoring units 222 .
  • Such a structure can make the anchor fit the shape of the entire ventricle, better grasp the tissue, and thus form a better anchoring force.
  • the anchoring unit 222 is made of a shape memory material, such as a shape memory alloy (nickel-titanium alloy), or a shape memory polymer material. Therefore, the anchoring unit 222 can be crimped into the delivery device for delivery, and can return to the original state for anchoring after being released to the target position.
  • a shape memory alloy nickel-titanium alloy
  • the center of the spacer 221 is configured with a central hole Q for fixing the connecting piece 210 , and the connecting piece 210 is fixed through the central hole Q with a wire knot.
  • a plurality of anchoring units 222 are evenly distributed along the circumferential direction of the spacer 221, so that the anchors can provide stable and effective anchoring force; and one end of the anchoring units 222 is fixed in the central hole Q Between the edge of the spacer 221 and the edge of the spacer 221 , one end of the anchoring unit 222 will not be in contact with the tissue for friction, so as to prevent stress concentration, and at the same time, the strength of the spacer 221 will not be affected.
  • the free end of the anchoring unit 222 is configured to have a smooth surface to prevent damage to the tissue.
  • the anchoring unit 222 and the spacer 221 are manufactured separately, and then fixed by welding or the like. In some embodiments, the anchoring unit 222 and the spacer 221 can be manufactured integrally, such as by cutting.
  • the anchoring mechanism 220 and connector 210 of this embodiment are capable of resisting retrograde forces applied to the heart valve prosthetic device during ventricular systole to maintain the desired position of the heart valve on the native mitral valve.
  • the anchoring mechanism 220 can also be used for anchoring the tricuspid valve.
  • the heart valve prosthesis device of this embodiment can be delivered by the atrial septal route. Compared with the apical route, the atrial septal route through the femoral vein is less invasive and has a wider audience. Under the transatrial septal path, the anchoring mechanism 220 can be anchored in the apex, and can also be anchored in the ventricular wall. In the present embodiment, the anchoring in the apex is used as an example to illustrate. Specifically, the implantation method of this heart valve prosthesis device is as follows:
  • Step 1 As shown in Figure 4A, the delivery 201 enters the right atrium via the inferior vena cava, then passes through the atrial septum and the mitral valve to the vicinity of the apex of the heart, as shown, the distal end of the delivery 201 can pass through the apex of the heart opening.
  • Step 2 As shown in Figure 4B, the anchoring mechanism 220 is released by relative movement between it and a portion of the delivery 201 (eg, catheter or sheath).
  • a portion of the delivery 201 eg, catheter or sheath.
  • relative movement is meant that the anchoring mechanism 220 can be advanced through the catheter or sheath and out of the distal end of the delivery device 201 to be released. Further movement between the anchoring mechanism 220 and the catheter or sheath can effectively deploy the location of the anchoring mechanism 220, eg, pulling the anchoring mechanism 220 proximally against the tip of the heart, which can be done by pulling the suture or connector 210 to execute.
  • Step 3 As shown in Figure 4C, the catheter or sheath can be moved relative to the stent 110, releasing the stent 110, allowing the valve prosthesis to be fully released at the target location.
  • the catheter or sheath can be withdrawn proximally relative to the stent 110 .
  • the length of the connector 210 can be modified at this stage or any previous stage to adjust the tension of the connector 210 to allow the anchoring mechanism 220 to achieve an optimal anchoring force.
  • the connector 210 is fixed and cut, and then the delivery system is withdrawn to complete the release.
  • the above-mentioned heart valve prosthetic device can also be delivered via the apical approach, specifically, the implantation method is as follows:
  • Step 1 The delivery device 201 can be advanced through the tip of the heart to the vicinity of the native mitral valve.
  • the catheter or sheath is moved relative to the stent 110, gradually releasing the stent 110, skirt, and prosthetic valve leaflets, allowing the valve prosthesis to be deployed at the target location.
  • the position of the valve prosthesis can be adjusted by the connector 210 .
  • Step 2 The sheath can be moved proximally relative to the stent 110 such that the distal end of the catheter or sheath is positioned outside the heart.
  • the anchoring mechanism 220 is released by relative movement between it and the catheter or sheath of the delivery 201 .
  • relative movement is meant that the anchoring mechanism 220 can be advanced in a direction towards the heart (distal end) through the catheter or sheath.
  • the anchoring mechanism 220 is slowly released. Further movement between the anchoring mechanism 220 and the catheter or sheath can effectively deploy the position of the anchoring mechanism 220, fully releasing the anchoring mechanism 220 at or near the apex of the heart.
  • the length of the connector 210 can be modified at this stage or any previous stage to adjust the tension of the connector 210 to allow the anchoring mechanism 220 to achieve an optimal anchoring force.
  • Step 3 Finally, fix and cut the connector 210, and then withdraw from the conveying system to complete the release.

Abstract

La présente invention concerne un mécanisme d'ancrage de valvule cardiaque (220) et un dispositif de prothèse de valvule cardiaque (100). Une extrémité d'une valvule cardiaque est pourvue d'un connecteur (210) s'étendant dans une direction axiale ; et le mécanisme d'ancrage (220) est conçu pour être fixé à une extrémité du connecteur (210), et comprend une entretoise (221) et un élément d'ancrage, l'entretoise (221) comprenant une première surface (2211) fixée à un tissu et une seconde surface (2212) opposée à la première surface (2211), et l'élément d'ancrage comprenant une pluralité d'unités d'ancrage (222). La pluralité d'unités d'ancrage (222) de l'élément d'ancrage sont respectivement fixées et ancrées au tissu, et sont également fixées à la surface du tissu au moyen d'une surface de l'entretoise (221) ; l'entretoise (221) peut fournir une surface relativement grande, de sorte que la concentration de contraintes peut être évitée, empêchant ainsi le tissu d'être usé par l'élément d'ancrage ; en outre, lorsque les unités d'ancrage (222) sont fixées au tissu, une force d'action est générée pour l'entretoise (221), laquelle force d'action peut faire en sorte que l'entretoise (221) se fixe fermement au tissu, réalisant ainsi les effets de fermeture hermétique d'une plaie et d'amélioration de l'ancrage, et la correspondance entre l'entretoise (221) et les unités d'ancrage (222) peut fournir un meilleur effet d'ancrage.
PCT/CN2021/099451 2021-02-03 2021-06-10 Mécanisme d'ancrage de valvule cardiaque et dispositif de prothèse de valvule cardiaque WO2022166062A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202120308029.1 2021-02-03
CN202120308029.1U CN216318211U (zh) 2021-02-03 2021-02-03 一种心脏瓣膜锚固机构及心脏瓣膜假体装置

Publications (1)

Publication Number Publication Date
WO2022166062A1 true WO2022166062A1 (fr) 2022-08-11

Family

ID=81128506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/099451 WO2022166062A1 (fr) 2021-02-03 2021-06-10 Mécanisme d'ancrage de valvule cardiaque et dispositif de prothèse de valvule cardiaque

Country Status (2)

Country Link
CN (1) CN216318211U (fr)
WO (1) WO2022166062A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022256198A1 (fr) * 2021-06-02 2022-12-08 Tendyne Holdings, Inc. Ancrage extensible pour valvule mitrale prothétique

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040260317A1 (en) * 2003-06-20 2004-12-23 Elliot Bloom Tensioning device, system, and method for treating mitral valve regurgitation
US20090276040A1 (en) * 2008-05-01 2009-11-05 Edwards Lifesciences Corporation Device and method for replacing mitral valve
US20130172978A1 (en) * 2011-12-16 2013-07-04 Tendyne Holdings Inc. Tethers for Prosthetic Mitral Valve
CN106344081A (zh) * 2016-09-28 2017-01-25 宁波迪创医疗科技有限公司 一种左心室减容机构
CN106821548A (zh) * 2017-04-01 2017-06-13 上海纽脉医疗科技有限公司 经导管人工二尖瓣成形环装置及系统
CN109745149A (zh) * 2017-11-07 2019-05-14 先健科技(深圳)有限公司 心脏瓣膜锚固装置及心脏瓣膜
WO2020154797A1 (fr) * 2019-01-28 2020-08-06 Vesalius Cardiovascular Inc. Appareil destiné à être utilisé dans la réparation de valves mitrales et son procédé d'utilisation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040260317A1 (en) * 2003-06-20 2004-12-23 Elliot Bloom Tensioning device, system, and method for treating mitral valve regurgitation
US20090276040A1 (en) * 2008-05-01 2009-11-05 Edwards Lifesciences Corporation Device and method for replacing mitral valve
US20130172978A1 (en) * 2011-12-16 2013-07-04 Tendyne Holdings Inc. Tethers for Prosthetic Mitral Valve
CN106344081A (zh) * 2016-09-28 2017-01-25 宁波迪创医疗科技有限公司 一种左心室减容机构
CN106821548A (zh) * 2017-04-01 2017-06-13 上海纽脉医疗科技有限公司 经导管人工二尖瓣成形环装置及系统
CN109745149A (zh) * 2017-11-07 2019-05-14 先健科技(深圳)有限公司 心脏瓣膜锚固装置及心脏瓣膜
WO2020154797A1 (fr) * 2019-01-28 2020-08-06 Vesalius Cardiovascular Inc. Appareil destiné à être utilisé dans la réparation de valves mitrales et son procédé d'utilisation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022256198A1 (fr) * 2021-06-02 2022-12-08 Tendyne Holdings, Inc. Ancrage extensible pour valvule mitrale prothétique

Also Published As

Publication number Publication date
CN216318211U (zh) 2022-04-19

Similar Documents

Publication Publication Date Title
US5957977A (en) Activation device for the natural heart including internal and external support structures
US20100217382A1 (en) Mitral valve replacement with atrial anchoring
BR112015021968B1 (pt) Montagem de válvula cardíaca bioprotética
CN112438825A (zh) 一种经房间隔植入的二尖瓣瓣膜装置及植入方法
WO2023015601A1 (fr) Dispositif de réparation de traitement d'une régurgitation tricuspidienne
CN210056341U (zh) 心脏瓣膜
EP3689298A1 (fr) Prothèse de valve cardiaque
CN114533347A (zh) 人工心脏瓣膜的锚固装置及人工心脏瓣膜系统
WO2022166062A1 (fr) Mécanisme d'ancrage de valvule cardiaque et dispositif de prothèse de valvule cardiaque
EP4327781A1 (fr) Valve cardiaque artificielle
US11938022B2 (en) Transcatheter valve prosthesis and method for implanting the same
WO2022105054A1 (fr) Dispositif de valvule mitrale implanté par l'intermédiaire d'un septum auriculaire, et procédé d'implantation
CN112107392A (zh) 一种人工心脏瓣膜支架及人工心脏瓣膜
CN214549745U (zh) 用于植入心脏的瓣膜假体装置
CN112438826A (zh) 一种用于植入心脏的瓣膜假体装置
CN212261612U (zh) 一种人工心脏瓣膜的植入装置
WO2022166064A1 (fr) Dispositif de valve implantable
CN214805711U (zh) 一种经房间隔植入的二尖瓣瓣膜装置
CN114848233A (zh) 人工瓣膜组件、植入系统及植入方法
CN111991121A (zh) 一种自膨胀房室瓣假体装置
WO2022236928A1 (fr) Dispositif d'ancrage pour prothèse d'implant cardiaque et prothèse d'implant cardiaque le comprenant
CN218832964U (zh) 一种锚固装置及人工心脏瓣膜装置
WO2022105055A1 (fr) Dispositif prothétique de valve destiné à être implanté dans le coeur
CN111616835A (zh) 一种人工心脏瓣膜的植入装置
CN218832965U (zh) 心脏植入物假体的锚固装置及包含其的心脏植入物假体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21924069

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21924069

Country of ref document: EP

Kind code of ref document: A1